gufic - nse india
TRANSCRIPT
GUFIC BIOSCIENCES LIMITED
Corp. Office: 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 05 7. Tel (91-22) 67261000 Fax· (91-22) 67261068 E-mail· [email protected]. CIN No. L24100MH19 84PLC033519
SO/LG/SE/JUNE /2021/GBSL
June 04, 2021
To The Manager (CRD) BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001
Scrip Code : 509079
Dear Sirs/Mam,
To The Manager National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051
Symbol : GUFICBIO
Sub: Outcome of the Board of Directors Meeting
The Board of Directors of the Company at its Meeting held on June 04, 2021,
which commenced at 4:00 p.m. and concluded at 08.10 p.m. on June 04, 2021, inter alia
considered and approved the following:
1. Allotment of 1,91,14,506 Equity Shares of the Company of FV of Re. 1/- each to theShareholders of Gufic Lifesciences Private Limited ("Transferor Company" or"GLPL") pursuant to the Scheme of Amalgamation of Gufic Lifesciences PrivateLimited ('Transferor Company') with the Company ('Transferee Company') andtheir shareholders and creditors.
Accordingly, the Paid-up Share Capital of the Company has increased from Rs. 7,78,30,000 /- (7,78,30,000 equity shares of face value of Re. 1/- each) to Rs. 9,69,44,506/
(9,69,44,506 equity shares of face value Re. 1/- each).
2. The Audited Financial Results for the quarter and financial year ended March 31,
2021. Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015, find enclosed herewith the said resultstogether with, Auditors Report, Declaration of unmodified opinion, ManagementReport and Investor Presentation. These are also being made available on thewebsite of the Company at www.gufic.com
Regd. Off 37. First Floor. Kamala Bhavan II. S. Nityananad Road. Andheri (East). Mumbai - 400 069 www.gufic.com
DeliveringCare&CureDeliveringCare&Cure
Gu�icmovingintherightdirectionGu�icmovingintherightdirection
DisclaimerDisclaimer
Except for the historical information contained herein, statements in this presentation and the subsequent
discussionsmayconstitute"forward-lookingstatements".Theseforward-lookingstatementsinvolveanumberof
risks, uncertainties including impact of Covid-19 and other factors that could cause actual results to differ
materiallyfromthosesuggestedbytheforward-lookingstatements.Theserisksanduncertaintiesinclude,butare
notlimitedtoourabilitytosuccessfullyimplementourstrategy,ourgrowthandexpansionplans,ourabilityto
obtainregulatoryapprovals,technologicalchanges,�luctuationinearnings,foreignexchangerates,ourabilityto
manageinternationaloperationsandexports,ourexposuretomarketrisksaswellasotherrisks.
Theinvestorpresentationisnotintendedtoendorse,advertise,promoteorrecommendtheuseofanyproducts
listed in itwhichare forrepresentationpurposeonly,someofwhicharereference listeddrugsofwhichthe
Companyhasapproved,underapprovalorunderdevelopmentgenericequivalents.
Theproductinformationcontainedhereinisnotintendedtoprovidecompletemedicalinformation,andisnot
intendedtobeusedasanalternativetoconsultingwithquali�ieddoctorsorhealthcareprofessionals.
Nothingcontainedhereinshouldbeconstruedasgivingofadviceorthemakingofarecommendationandit
shouldnotbereliedonasthebasisforanydecisionoraction.Itisimportanttoonlyrelyontheadviceofahealth
careprofessional.
Aesthaderm- launchedinJanuary2021:Comprisesof“Stunnox”brand(the�irst indigenouslymanufactured
botulinum toxin inj in collaborationwithPrimeBio -USA)& researchbased cosmetic formulations suchas
Moiseta,RevanoxandXtrasun(incollaborationwithLucasMeyer,France).
StunnoxTypeA-launchedinFeb2021andhasseenapositivefeedbackinpost-launchtrialsundertakenon100
patients.Thesafetyandef�icacyoftheproductisexcellentandwellaccepted.Thismakeusverycon�identonthe
futureprospectsofStunnoxTypeEandStunnoxTypeOwhichareoncoursefor2023-24.
Contractmanufacturingdivisiongrewby15%YoY,aidedbythemergerofGu�icLifesciencesPvtLtd&contract
manufacturingbusinessofRemdesivir(served~5mndoses)
ndDuetothe2 waveofCovid-19pandemicandcriticalissueofBlackFungus,theCriticalCareproductportfolio
continueditsunprecedentedgrowth.However,thegrowthoftheotherproductswasrelativelymuted.
ExportsweredrivenbysalesinGermany,Portugal,Myanmar,SriLanka,ColombiaandPhilipinesandalargeone-
timesupplyopportunitytoSouthAmerica,whichhelpedtoposta50%growth.FromFY-21-22,thecompany
expectstoventureintonewermarketssuchasBrazil,Canada,SouthAfricaandRussia
FY2020-21:BusinessOverview
APIdivisiongrewby40%aidedbyincreasedcapacitiesandsubstantialinvestmentsinproductdevelopment.We
aimtolaunch5newmoleculesinFY22.
ThecompanyisinprocessofapplyingforIS-6(oneofthemoleculesfortreatmentofBlackfungus).Expediated
approvalbytheDCGImaybeexpectedgiventhecurrentsituationinthecountry.
ImmunocinAlpha(ThymosinAlpha-1)trialdataforCovid-19willbesubmittedtoDCGIbyJune2021fortheir
review.
Gu�iclaunched2brandsofPre�illedsyringeinQ32020forcardiacconditionswhichalsohashugepotentialin
Covid-19.Healthygrowthisexpectedin2021-22fromthesebrands.Thedevelopment3newbiologicalpeptides
inthe�ieldofgynaecologyareprogressingwellandexpectedtobecommercializedbyQ2/Q3FY2022.
Gu�ichasinvestedinthedevelopmentofH15-acandidateforAsthmaand3newNDDSformulationsforAnti-
infectiveuse.
Gu�ichastiedupwithMetaversoTS,PortugaltolaunchaseriesofrecombinantmoleculesinIndia,�irstofwhich
willbeinthe�ieldofinfertility.Thiswillbethe�irstrecombinantproducttobemanufacturedin-house.
FY2020-21:BusinessOverview
Movingintherightdirection…tocreatehealthylives!Movingintherightdirection…tocreatehealthylives!
Gu�ic is a fast-growing research based pharmaceutical company recognized for its innovative, high-quality Pharmaceuticals, Nutraceuticals, Natural/Herbal products.
Gu�ic is one of the fastest growing company among the top 100 pharma companies in India
Gu�ic is one of largest manufacturers of Lyophilized injection in India with a wide range of products in various therapy areas.
The Ranking progression as per IQVIA is
Company Rank 2018 Rank 2019 Rank 2020 Rank 2021
GUFIC 102 94 93 86
Source:IQVIAApr-21
Movingintherightdirection...withawellde�inedbusinessstructure
DomesticBusiness
ExclusivefacilityforAPI.Specializationin-Anesthetics-AntiFungal-Antibiotic
Operationspreadacrossmorethan20countries.
130+productsregisteredglobally
150+productsinpipelineforregistration
8wellde�inedStrategicBusinessUnits
Fieldforceof~1000
ProductPortfolioin15+TherapyAreas
Contractmanufacturing
Business
OneofthelargestfacilityforLyophilization
70+CMOPartners
50+Products
BulkDrugBusiness
InternationalBusiness
OurbroadBusinessStructureOurbroadBusinessStructure
Movingintherightdirection...toscale-upthemanufacturingfacility
•Lyophilized–30million(mn)vialsperannum(p.a.)PFS–30mnPFSp.a•
SanitaryNapkins-•8.4mnperannum(p.a)
•60mncapsulesp.a•3.6mnpowderp.a
•Lyophilized–18million(mn)vialsperannum(p.a.)•Ampoule–12mnp.a.•Ointment–6mntubesp.a.•Lotion–6mnbottlesp.a.•Syrup–6mnbottlesp.aPFS–2.8mnPFSp.a•
CAPACITY
EUGMP(Hungary),ANVISABrazil,RussianGMP,HealthCanada,UkraineGMP,AustraliaTGA,ColombiaINVIMA,WHOGMP,UgandaNDA
WHOGMP,PhilippinesBFAD,NigeriaNAFDAC,CambodiaMOH,KenyaPPB,EthiopiaFMHACA,ThailandMOH,SrilankaNMRA
CERTIFICATIO
NS
Naturalproductsfacility
Gu�ic-Belgaum
SanitaryNapkinsfacility
Gu�ic-Vadodara
Lyophilizedinjectablesfacility
Unit-II
WorldClassManufacturingInfrastructureWorldClassManufacturingInfrastructure
Gu�icBiosciencesLtd
Lyophilized/powderinjectablesfacility
BotulinumToxinfacility
NaturalProducts(Topical/Liquid) APIfacility Capabilitytomanufacture
LiposomalAmphotericin-BandDepotInjections
Unit-I
Movingintherightdirection...toscale-upthemanufacturingfacility
UpcomingWorldClassManufacturingInfrastructureUpcomingWorldClassManufacturingInfrastructure
Gu�icBiosciencesLtd
Carbapenems(Lyophilized/DryPowderInj.
/OralSolids)
PenemBlock
•Lyophilized–3mnvialsperannum(p.a.)•OralSolids–30mn(Tab/Cap)p.a.
Gu�icBiosciencesLtd
Unit-III Unit-IV
CapabilitytocaterregulatedmarketssuchasUS&EU
Lyophilizedinjectablesfacility
•Lyophilized–36mnvialsperannum(p.a.)LiquidInjections–43mnunitsp.a•
CAPACITY
Gu�icBiosciencesManufacturingFacility
Gu�ic Biosciences Ltd is a WHO GMP, EU GMP,
ANVISA Brazil, Russian GMP, Health Canada, Ukraine
GMP, Australia TGA, Colombia INVIMA and Uganda NDA
approved company with a total capacity of 30 million
lyophilized vials per annum.
Product portfolio includes Antibiotic, Antifungal, Cardiac,
Antiviral and proton-pump inhibitor segments
Exporting - Vancomycin, Clarithromycin, Azithromycin and
Omeprazole injection to EU countries.
Gu�icBiosciencesManufacturingFacility
B o
B o
BotulinumToxinFacilityBotulinumToxinFacility
Gu�ichasbuiltastate-of-the-artmanufacturingfacilityforBotulinumToxininNavsari,India.
B o
Gu�ic has partnered with Prime Bio, USA for
manufacturing Botulinum Toxin API and formulation.
Guc is equipped with all the necessary analytical
testing procedures for safety and efcacy of Botulinum
toxin
Guc and Prime-bio, to develop several innovative
formulations with Botulinum toxin in the eld
Dermatology, Neurology and Pain Management.
Movingintherightdirection...toExploretheInternationalBusiness
PRESENCE IN STRATEGIC LOCATIONS ACROSS THE GLOBE
ExpandingourGeographicalReachExpandingourGeographicalReach
Ouroperationsisspreadpan-Indiaand20+countriesworldwide
• • • • • • • • • • • • • CANADA COSTA RICA PANAMA COLUMBIA CHILE LATVIA LITHUANIA BELARUS GERMANY AUSTRIA PORTUGAL MOROCCO ALGERIA OMINICAN REPUBLIC VENEZUELA SUDAN ETHIOPIA ECUADOR PERU PARAGUAY NIGERIA SOUTH AFRICA EGYPT ZIMBABWE UGANDA• • • • • • • • • • • • • IRAN YEMEN SRI LANKA MYANMAR PHILIPPINES THAILAND CAMBODIA VIETNAM MALAYSIA UKRAINE JORDAN SYRIA GEORGIA • • • • • • • • • • • • •
• • • • • UZBEKISTAN KAZAKHSTAN NEPAL RUSSIA AUSTRALIA
130+ Products registered globally (in 15+ countries)
150+ products in pipeline for registration (in 30+ countries)
EXISTINGPRESENCEMAPNOTTOSCALE
Movingintherightdirection…tobuildourdomesticbusiness
ConsolidatingourIndiaBusinessConsolidatingourIndiaBusiness
Pan-IndiaPresenceinmultipleTherapyAreas
IndiaBusiness
Doctorreach : Over 1,20,000Prescribers : 30,000Retailreach : 1,10,000HospitalCoverage : 80 % of Tertiary care, Key Account Manager Infrastructure
in place Presence in Government Institutions
CriticalCare
FieldForce:>250
Therapyareas:Antibacterial,Antifungal,PainManagement,Bloodproducts,GIImmuno-modulator
Infertility
FieldForce:>150
Therapyareas:Hormones,RecombinantProducts,InfertilitySupplements
Natural&NutraceuticalProducts
FieldForce:>300
Therapyareas:BoneHealth,PainManagement,Immunity,Gastro,Stress,Nutraceuticals,Woundcare,Respiratory,Gynaec
MassSpecialty
FieldForce:>180
Therapyareas:Anti-Infectives,Gastro,Gynaecology,Respiratory,Nutraceuticals,Dermaology
FieldForce:>60
Therapyareas:BoneHealth,PainManagement,Fractures,Arthritis,Pregnancy,PostMenopausal
Ortho-GynaecProducts
FieldForce:>40
Therapyareas:Neurotoxin,Emollients,Antiaging,Cleansers,Pre&PostProcedure,Hyperpigmentation,Sunscreens
Dermo-CosmeticProducts
STELLAR Aesthaderm
Movingintherightdirection...inwidespreadTherapyareas
Gu�ic-Wide-spreadTherapyPresenceGu�ic-Wide-spreadTherapyPresence
Portfolioofover100productsand200SKUs
Venturingintonewfuturistictherapyareaslike-BiologicalsandImmuno-Oncology
BloodRelatedAntiFungalAnti-Infectives
Hormones Respiratory Osteoporosis Arthritis
PainManagement WoundCare Hepatoprotectives Immunity Infertility
Gastrointestinal WomenHealth
ProductofferingsinMultipletherapyareasacrossthepharmaceuticalmarket
Dermo-Cosmetics
Movingintherightdirection...WithstronggrowthorientedLicensingdeals
Gu�ic-OurstrongPartnershipandlicensingdealsGu�ic-OurstrongPartnershipandlicensingdeals
Gu�icbelievesinlong-termmutuallybene�icialpartnershipbasedonseveralbusinessmodels
Ready to market
Tech-transfer
API and formulation development
Prot sharing / Royalty
Therapyarea:Dermo-cosmeticsTechnical collaboration and Product Development
Therapyarea:InfertilityTech-transfer and Clinical development(Phase-III) of the product at Gu�ic
Therapyarea:Toxins-Strain transfer, Tech-transfer, formulation development and manufacturing at Gu�icB o
Therapyarea:RecombinantproductsandAnti-InfectivesCollaborationonseveralAPItodevelopnewproduct
ExtensiveSales,Distribution&ITInfrastructureinIndiaExtensiveSales,Distribution&ITInfrastructureinIndia
Pan India Presence with a eld force > 1000+
Two central ware house located in North-Delhi & West-Bhiwandi
23 Carrying & Forwarding agents across India
1200 Stockists for effective distribution across India.
Retail coverage of more than 1,10,000 retailer.
2CentralWarehouses 23C&FAgents 1200PlusStockists 1000+FieldForce
ITInfrastructure
Integrated IT systems with Sales and Distribution Infrastructure
SAP S4 HANA (being Implemented) across all Departments
Tablets, Sales Force Automation and Effectiveness tools in place
Movingintherightdirection...asreliableCMOpartners
GUFIC-ExpandingOurcredibilityIntheCMOBusinessGUFIC-ExpandingOurcredibilityIntheCMOBusiness
WeofferCMOservicesforIndiaandGlobalmarkets:
Reliable CMO service for quality products over a decade
70 + Companies
150 + Products across multiple therapy areas
One of the Largest supplier of formulations-Doxycycline, Tigecycline, Gonadotropins, Liposomal Amphotericin-B, Micafungin, Remdesivir (Served ~ 5 mn Doses)
OurEsteemedPartners
OurrobustR&DandClinicalteamtoaugmentgrowthOurrobustR&DandClinicalteamtoaugmentgrowth
Movingintherightdirection…tocreatefuturemarkets
R&D
State-of-the-artR&DFacilitylocatedinNavsari,Gujaratwithexpertisein
FormulationDevelopment
Technology-Transfer
APIDevelopment
ClinicalTeam
StrongClinicalteamcomprisingof
Medical
Regulatory
ProductDevelopment
CapabilitiestotakeSyntheticandBiologicalProjectsacrossPhaseIIandPhaseIIIclinicaltrials
Patentsinvarioustherapyareas
Granted:5
Filed:4
MajorProjectsinPipeline:
50+acrossalltherapyareas
Anti-Infectives:11
Dermatology:7
Gynaec:6
CNS:4
Anti-Fungal:3
Oncology:3
ProjectsinvariousClinicalPhases
On-going:5
Pipeline:12
PharmacovigilanceTeam
Special/NDDSProjects
InnovativeformulationsofBotulinumToxin
LiposomalAmphotericin-BInjection
DepotInjection
DualChamberIVBags
DualChamberSyringes
BuildingourAPICapabilitiesBuildingourAPICapabilities
Movingintherightdirection...tocreateAPIcapabilities
Special facility dedicated to API
The categories of API’s manufactured are antifungals, antibacterial, anesthetics and intermediates for antifungals
Presence in 25+ countries worldwide
70+ customers Pan India
Gu�ic-OurStrategicGrowthLeversGu�ic-OurStrategicGrowthLevers
Movingintherightdirectiontoboostfuturegrowth
InternationalBusiness
IndiaBusiness
CMOBusiness
StrategicGrowthlevers
Consolidation of the Critical Care / Infertility business
Entry into new therapy areasDermatology - Aesthaderm
Strategic focus on Healthcare division with entry into Ortho-Gynecology products through a new division - Stellar
Build a robust pipeline of new products
Build up the licensing products portfolio
Expand our presence in regulated markets such as US & EU
Gradually commercialize the pipeline products
Explore newer geographical locations
Scale - up the manufacturing capacity
Consolidation of the clients - offer more products to existing clients
Expand the customer base
New product offerings
-
FinancialHighlights–FY2020-21FinancialHighlights–FY2020-21
AmtinLacs
Quarterly YTD
Particulars Q4FY21 Q4FY20 Growth YTDFY21 YTDFY20 Growth
NetSales 13,093 8,707 50% 48,670 37,884 28%
EBITDA 2,440 1,365 79% 8,765 5,791 51%
EBIDTAMargin% 19% 16% 18% 15%
Pro�itBeforeTax(PBT) 1,705 629 171% 5711 3013 92%
PBTMargin% 13% 7% 12% 8%
NetPro�it 1287 197 159% 4423 2269 95%
Debt/EquityRatio 0.32 0.90
OperatingCash�lows 8907 4710 89%
FinancialHighlights–FY2020-21FinancialHighlights–FY2020-21
24,927
30,874
35,41737,884
48,670
FY17 FY18 FY19 FY20 FY21
CAGR- 18.21%
REVENUE
2,795
4,323
5,668 5,791
8,765
11% 14% 16% 15% 18%-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
FY17 FY18 FY19 FY20 FY21
CAGR- 33.07%
EBIDTA
EBIDTA EBIDTAMargin%
1,141
1,648
2,678
2,269
4,423
5% 5% 8% 6% 9%-
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
5,000
FY17 FY18 FY19 FY20 FY21
CAGR- 40.32%
NETPROFIT
NetPro�it NetPro�itMargin%
10,000
20,000
30,000
40,000
50,000
60,000
FinancialHighlights–FY2020-21FinancialHighlights–FY2020-21
24.48%
17.54%
25.50%
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
FY19 FY20 FY21
ROE%
24.16%
18.21%
32.05%
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
FY19 FY20 FY21
ROCE%
CorporateCitizenshipCorporateCitizenship
COMMUNITYHEALTHCARE,SANITATIONANDHYGIENE
EDUCATION,KNOWLEDGEANDRESEARCH
SOCIALCAREANDCONCERN
Assist people living in areas having inadequate medical facilities to get medical assistance
Provide free sanitary napkins for under privileged women
Provide world class medicines at cost price for 2500 patients annually
Assist underprivileged children to avail education
Promote sports
Work with academic institutions and provide access to sophisticated analytical equipment not available with them at zero cost
Generate employment opportunities
Welfare of victims of natural calamities
Save the Girl Child campaign
Gu�ic’s strong focus onpromoting and supportingthecauseofchildeducationhas been recognized bySmileFoundation
ThankYouThankYou
Foranyqueries,pleasecontact AvikDas
AmiShah(Compliance Officer) [email protected]:+91-22-67261000